Вопросы вирусологии. 2017; 62: 266-272
БЕЗОПАСНОСТЬ И ИММУНОГЕННОСТЬ ХОЛОДОАДАПТИРОВАННОГО ГРИППОЗНОГО ВЕКТОРА, ЭКСПРЕССИРУЮЩЕГО АНТИГЕНЫ ESAT-6 И AG85А M. TUBERCULOSIS
https://doi.org/10.18821/0507-4088-2017-62-6-266-272Аннотация
Список литературы
1. World Health Organization. Global Tuberculosis Report 2016. Available at: http://www.who.int/tb/publications/global_report/en/
2. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol. Rec. 2004; 79(4): 27-38.
3. Ottenhoff T.H., Kaufmann S.H. Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? PLoS Pathog. 2012; 8(5): e1002607.
4. Стукова М.А., Заболотных Н.В., Виноградова Т.И., Гергерт В.Я., Апт А.С., Капрельянц А.С. и др. Профилактика туберкулёза: современные подходы к разработке противотуберкулёзных вакцин. Вестник Российской академии медицинских наук. 2012; (11): 45-52
5. Stukova M.A., Sereinig S., Zabolotnyh N.V., Ferko B., Kittel C., Romanova J., et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis. 2006; 86(3-4): 236-46.
6. Kuznetsova I., Shurygina AP., Wolf B., Wolschek M., Enzmann F., Sansyzbay A., et al. Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector. J. Gen. Virol. 2014; 95(Pt. 2): 337-497.
7. Заболотных Н.В., Шурыгина А.-П.С., Виноградова Т.И., Витовская М.Л., Хайруллин Б.М., Сандыбаев Н.Т. и др. Усиление протективного эффекта вакцины БЦЖ при мукозальной буст-иммунизации гриппозным вектором, экспрессирующим микобактериальные белки ESAT-6 и Ag85A. Биофармацевтический журнал. 2016; 8(6): 25-31
8. Flórido M., Pillay R., Gillis C.M., Xia Y., Turner S.J., Triccas J.A., et al. Epitope-specific CD4+, but not CD8+, T-cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection. Eur. J. Immunol. 2015; 45(3): 780-93.
9. Ferko B., Stasakova J., Sereinig S., Romanova J., Katinger D., Niebler B., et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J. Virol. 2001; 75(19): 8899-908.
10. Kittel C., Ferko B., Kurz M., Voglauer R., Sereinig S., Romanova J., et al. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J. Virol. 2005; 79(16): 10672-7.
11. Egorov A., Brandt S., Sereinig S., Romanova J., Ferko B., Katinger D., et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J. Virol. 1998; 72(8): 6437-41.
12. Цыбалова Л.М., Горев Н.Е., Потапчук М.В., Репко И.А., Коротков А.В., Сергеева М.В. и др. Характеристика холодоадаптированного штамма вируса гриппа А/Гонконг/1/68/162/35 (H3N2) как потенциального донора аттенуации и высокой репродуктивности. Вопросы вирусологии. 2012; 57(6): 13-7.
13. Пулькина А.А., Сергеева М.В., Петров С.В., Фадеев А.В., Комиссаров А.Б., Романовская-Романько Е.А. и др. Влияние мутаций в нуклеопротеине на репликацию реассортантов вируса гриппа А/Гонконг/1/68/162/35 при различных температурах. Молекулярная биология. 2017; 51(2): 378-83.
14. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 1938; 27: 493-7.
15. Gasteiger E., Hoogland C., Gattiker A. Duvaud S., Wilkins M.R., Appel R.D., et al. Protein Identification and Analysis Tools on the ExPASy Server. In: Walker J.M., ed. The Proteomics Protocols Handbook. Totowa, NJ: Humana Press; 2005: 571-607.
16. Vasin A.V., Petrova A.V., Egorov V.V., Plotnikova M.A., Klotchenko S.A., Karpenko M.N., et al. The influenza A virus NS genome segment displays lineage-specific patterns in predicted RNA secondary structure. BMC Res. Notes. 2016; (9): 279.
17. Пулькина А.А., Сергеева М.В., Синцова К.С., Комиссаров А.Б. Влияние особенностей структуры РНК на генетическую стабильность вставки туберкулёзных антигенов в гриппозном векторе. В кн.: Неделя науки СПбПУ. Материалы научной конференции с международным участием. СПб.; 2016: 492-5
18. Isakova-Sivak I., Tretiak T., Rudenko L. Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. Expert. Rev. Vaccines. 2016; 15(10): 1241-3
19. Третяк Т.С., Исакова-Сивак И.Н., Кореньков Д.А., Смолоногина Т.А., Руденко Л.Г. Анализ ростовых характеристик векторных вакцин против респираторно-синцитиального вируса. Медицинский академический журнал. 2016; 16(4): 171-2
20. Romanova J.R., Ermachenko T.A., Alexandrova G.I., Tannock G.A. Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice. Vaccine. 1994; 12(1): 23-7.
21. Chen H., Matsuoka Y., Swayne D., Chen Q., Cox N.J., Murphy B.R., et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine. 2003; 21(27-30): 4430-6.
22. Дешева Ю.А., Лу Х., Рекстин А.Р., Кац М.Д., Руденко Л.Г., Климов А.И. Прививочные свойства реассортантного холодоадаптированного штамма вируса гриппа A(H5N2) при интраназальном введении мышам. Вопросы вирусологии. 2007; 52(4): 27-30
23. Huygen K. The Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosis. Front. Immunol. 2014; (5): 321.
24. Thakur A., Pedersen L.E., Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012; 30(33): 4907-20.
25. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 2005; 174(10): 6332-9.
Problems of Virology. 2017; 62: 266-272
SAFETY AND IMMUNOGENICITY OF COLD-ADAPTED RECOMBINANT INFLUENZA VECTOR EXPRESSING ESAT-6 AND AG85А ANTIGENS OF M. TUBERCULOSIS
https://doi.org/10.18821/0507-4088-2017-62-6-266-272Abstract
References
1. World Health Organization. Global Tuberculosis Report 2016. Available at: http://www.who.int/tb/publications/global_report/en/
2. World Health Organization. BCG vaccine. WHO position paper. Wkly Epidemiol. Rec. 2004; 79(4): 27-38.
3. Ottenhoff T.H., Kaufmann S.H. Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go? PLoS Pathog. 2012; 8(5): e1002607.
4. Stukova M.A., Zabolotnykh N.V., Vinogradova T.I., Gergert V.Ya., Apt A.S., Kaprel'yants A.S. i dr. Profilaktika tuberkuleza: sovremennye podkhody k razrabotke protivotuberkuleznykh vaktsin. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2012; (11): 45-52
5. Stukova M.A., Sereinig S., Zabolotnyh N.V., Ferko B., Kittel C., Romanova J., et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis. 2006; 86(3-4): 236-46.
6. Kuznetsova I., Shurygina AP., Wolf B., Wolschek M., Enzmann F., Sansyzbay A., et al. Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector. J. Gen. Virol. 2014; 95(Pt. 2): 337-497.
7. Zabolotnykh N.V., Shurygina A.-P.S., Vinogradova T.I., Vitovskaya M.L., Khairullin B.M., Sandybaev N.T. i dr. Usilenie protektivnogo effekta vaktsiny BTsZh pri mukozal'noi bust-immunizatsii grippoznym vektorom, ekspressiruyushchim mikobakterial'nye belki ESAT-6 i Ag85A. Biofarmatsevticheskii zhurnal. 2016; 8(6): 25-31
8. Flórido M., Pillay R., Gillis C.M., Xia Y., Turner S.J., Triccas J.A., et al. Epitope-specific CD4+, but not CD8+, T-cell responses induced by recombinant influenza A viruses protect against Mycobacterium tuberculosis infection. Eur. J. Immunol. 2015; 45(3): 780-93.
9. Ferko B., Stasakova J., Sereinig S., Romanova J., Katinger D., Niebler B., et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J. Virol. 2001; 75(19): 8899-908.
10. Kittel C., Ferko B., Kurz M., Voglauer R., Sereinig S., Romanova J., et al. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J. Virol. 2005; 79(16): 10672-7.
11. Egorov A., Brandt S., Sereinig S., Romanova J., Ferko B., Katinger D., et al. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J. Virol. 1998; 72(8): 6437-41.
12. Tsybalova L.M., Gorev N.E., Potapchuk M.V., Repko I.A., Korotkov A.V., Sergeeva M.V. i dr. Kharakteristika kholodoadaptirovannogo shtamma virusa grippa A/Gonkong/1/68/162/35 (H3N2) kak potentsial'nogo donora attenuatsii i vysokoi reproduktivnosti. Voprosy virusologii. 2012; 57(6): 13-7.
13. Pul'kina A.A., Sergeeva M.V., Petrov S.V., Fadeev A.V., Komissarov A.B., Romanovskaya-Roman'ko E.A. i dr. Vliyanie mutatsii v nukleoproteine na replikatsiyu reassortantov virusa grippa A/Gonkong/1/68/162/35 pri razlichnykh temperaturakh. Molekulyarnaya biologiya. 2017; 51(2): 378-83.
14. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Epidemiol. 1938; 27: 493-7.
15. Gasteiger E., Hoogland C., Gattiker A. Duvaud S., Wilkins M.R., Appel R.D., et al. Protein Identification and Analysis Tools on the ExPASy Server. In: Walker J.M., ed. The Proteomics Protocols Handbook. Totowa, NJ: Humana Press; 2005: 571-607.
16. Vasin A.V., Petrova A.V., Egorov V.V., Plotnikova M.A., Klotchenko S.A., Karpenko M.N., et al. The influenza A virus NS genome segment displays lineage-specific patterns in predicted RNA secondary structure. BMC Res. Notes. 2016; (9): 279.
17. Pul'kina A.A., Sergeeva M.V., Sintsova K.S., Komissarov A.B. Vliyanie osobennostei struktury RNK na geneticheskuyu stabil'nost' vstavki tuberkuleznykh antigenov v grippoznom vektore. V kn.: Nedelya nauki SPbPU. Materialy nauchnoi konferentsii s mezhdunarodnym uchastiem. SPb.; 2016: 492-5
18. Isakova-Sivak I., Tretiak T., Rudenko L. Cold-adapted influenza viruses as a promising platform for viral-vector vaccines. Expert. Rev. Vaccines. 2016; 15(10): 1241-3
19. Tretyak T.S., Isakova-Sivak I.N., Koren'kov D.A., Smolonogina T.A., Rudenko L.G. Analiz rostovykh kharakteristik vektornykh vaktsin protiv respiratorno-sintsitial'nogo virusa. Meditsinskii akademicheskii zhurnal. 2016; 16(4): 171-2
20. Romanova J.R., Ermachenko T.A., Alexandrova G.I., Tannock G.A. Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice. Vaccine. 1994; 12(1): 23-7.
21. Chen H., Matsuoka Y., Swayne D., Chen Q., Cox N.J., Murphy B.R., et al. Generation and characterization of a cold-adapted influenza A H9N2 reassortant as a live pandemic influenza virus vaccine candidate. Vaccine. 2003; 21(27-30): 4430-6.
22. Desheva Yu.A., Lu Kh., Rekstin A.R., Kats M.D., Rudenko L.G., Klimov A.I. Privivochnye svoistva reassortantnogo kholodoadaptirovannogo shtamma virusa grippa A(H5N2) pri intranazal'nom vvedenii mysham. Voprosy virusologii. 2007; 52(4): 27-30
23. Huygen K. The Immunodominant T-Cell Epitopes of the Mycolyl-Transferases of the Antigen 85 Complex of M. tuberculosis. Front. Immunol. 2014; (5): 321.
24. Thakur A., Pedersen L.E., Jungersen G. Immune markers and correlates of protection for vaccine induced immune responses. Vaccine. 2012; 30(33): 4907-20.
25. Dietrich J., Aagaard C., Leah R., Olsen A.W., Stryhn A., Doherty T.M., et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy. J. Immunol. 2005; 174(10): 6332-9.
